Zurzuvae (Zuranolone): Uses, Side Effects, & More
Choosing Therapy strives to provide our readers with mental health content that is accurate and actionable. We have high standards for what can be cited within our articles. Acceptable sources include government agencies, universities and colleges, scholarly journals, industry and professional associations, and other high-integrity sources of mental health journalism. Learn more by reviewing our full editorial policy.
Deligiannidis, K. M., Meltzer-Brody, S., Maximos, B., Peeper, E. Q., Freeman, M., Lasser, R., Bullock, A., Kotecha, M., Li, S., Forrestal, F., Rana, N., Garcia, M., Leclair, B., & Doherty, J. (2023). Zuranolone for the Treatment of Postpartum Depression. The American journal of psychiatry, appiajp20220785. Advance online publication. Retrieved from https://doi.org/10.1176/appi.ajp.20220785
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression | Biogen. (2023). Biogen. Retrieved from https://investors.biogen.com/news-releases/news-release-details/biogen-and-sage-therapeutics-announce-fda-accepts-filing-new
Clayton, A. H., Lasser, R., Nandy, I., Sankoh, A. J., Jonas, J., & Kanes, S. J. (2023). Zuranolone in Major Depressive Disorder: Results From MOUNTAIN-A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. The Journal of clinical psychiatry, 84(2), 22m14445. Retrieved from https://doi.org/10.4088/JCP.22m14445
Food and Drug Administration USA. (2019). Is It Really “FDA Approved?” U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved